Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study

Si-wei Li; Xue Feng; Hao Xu; Ke-ji Chen

doi:10.1007/s11655-017-2419-7

Your Location：

Home >

Browse articles >

Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study

OriginalPaper | Updated：2021-08-27

- Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study
- Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study
- 中国结合医学杂志（英文版） 2018年24卷第2期页码：103-108
- Affiliations：
  
  1. Cardiovascular Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  2. Xiyuan Hospital, Postdoctoral Research Station of China Academy of Chinese Medical Sciences,Beijing,China
  3. Cardiac Rehabilitation Center, Fuwai Hospital, Chinese Academy of Medical Sciences,Beijing,China
- Author bio：
- Funds：
  
  Supported by the 1st-class General Financial Grant from the China Postdoctoral Science Foundation (No. 2016M590188)
- DOI：10.1007/s11655-017-2419-7
  中图分类号：
- 纸质出版日期：2018，
  
  网络出版日期：2017-10-25，
Scan for full text
Li, Sw., Feng, X., Xu, H. et al. Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study., Chin. J. Integr. Med. 24, 103–108 (2018). https://doi.org/10.1007/s11655-017-2419-7

Si-wei Li, Xue Feng, Hao Xu, et al. Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study[J]. Chinese Journal of Integrative Medicine, 2018,24(2):103-108.
Li, Sw., Feng, X., Xu, H. et al. Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study., Chin. J. Integr. Med. 24, 103–108 (2018). https://doi.org/10.1007/s11655-017-2419-7 DOI：

Si-wei Li, Xue Feng, Hao Xu, et al. Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study[J]. Chinese Journal of Integrative Medicine, 2018,24(2):103-108. DOI： 10.1007/s11655-017-2419-7.

摘要

To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin

heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer. Peripheral blood samples were extracted from 20 healthy volunteers

followed by adding different concentrations of puerarin

heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time (ACT)

clot rate (CR) and platelet function (PF) by Sonoclot coagulation and platelet function analyzer instrument. For puerarin and heparin sodium

the values of ACT gradually increased

and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear (or log linear) relationship between ACT

PF value and drug concentration (P<0.01). Corresponding to each value

a regression equation was obtained. For tirofiban hydrochloride

the values of ACT and CR had no significant changes

while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride (P<0.01). Under the same ACT values

the puerarin corresponding CR values (CR = e−0.0062ACT+4.31

P<2.2e-16) were always higher than the corresponding values (CR = e−0.0028ACT+2.79

P-value<2.2e-16) of heparin sodium. For high concentrations of puerarin (e.g. 3.8 mg/600 μL) and tirofiban hydrochloride (e.g. 0.8 μg/600 μL)

PF values had no significant difference. However

PF values for high puerarin concentration had a larger variance. Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium

and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition

for high concentration

puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.

Abstract

To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin

followed by adding different concentrations of puerarin

heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time (ACT)

clot rate (CR) and platelet function (PF) by Sonoclot coagulation and platelet function analyzer instrument. For puerarin and heparin sodium

the values of ACT gradually increased

and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear (or log linear) relationship between ACT

PF value and drug concentration (P<0.01). Corresponding to each value

a regression equation was obtained. For tirofiban hydrochloride

the values of ACT and CR had no significant changes

the puerarin corresponding CR values (CR = e−0.0062ACT+4.31

P<2.2e-16) were always higher than the corresponding values (CR = e−0.0028ACT+2.79

P-value<2.2e-16) of heparin sodium. For high concentrations of puerarin (e.g. 3.8 mg/600 μL) and tirofiban hydrochloride (e.g. 0.8 μg/600 μL)

PF values had no significant difference. However

PF values for high puerarin concentration had a larger variance. Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium

and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition

for high concentration

puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.

关键词

Puerarinheparintirofiban hydrochloridein vitroSonoclot coagulation analyzeranticoagulationantiplatelet aggregation

Keywords

Puerarinheparintirofiban hydrochloridein vitroSonoclot coagulation analyzeranticoagulationantiplatelet aggregation

references

Yin ZZ, Zeng GY. Pharmacology of puerarin. V. Effects of puerarin on platelet aggregation and release of 5-HT from platelets. Acta Acad Med Sin (Chin) 1981;3 Suppl 1:44–47.

Tuman KJ, Spiess BD, Mccarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69–75.

Chapin JW, Becker GL, Hulbert BJ, Newland MC, Cuka DJ, Wood RP, et al. Comparison of thromboelastograph and Sonoclot coagulation analyzer for assessing coagulation status during orthotopic liver transplantation. Transplant Proc 1989;21:3539–3539.

John JD, William AL, AJ Wright. Effective hemostasis in cardiac surgery. Anesthesiology 1989;71:325–326.

Yang X. The study of development of purring injection [dissertation]. Changchun: Jilin University; 2008.

Chen X, Chen WZ, Zeng GY. Cardiovascular pharmacology. 3rd ed. Beijing: People’s Medical Publishing House; 2002:520–523.

Lynch JJ Jr, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther 1995;272:20–32.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Induction of adhesion molecule expression in co-culture of human bronchial epithelial cells and neutrophils suppressed by puerarin via down-regulating p38 mitogen-activated protein kinase and nuclear factor κB pathways

In vitro and in vivo effects of puerarin on promotion of osteoblast bone formation

Effect of puerarin on the release of interleukin-8 in co-culture of human bronchial epithelial cells and neutrophils

Puerarin improve insulin resistance of adipocyte through activating Cb1 binding protein path

In vivo and in vitro antiviral effects of berberine on influenza virus